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Abstract
Background:  The human NOTCH 4 ge ne  is a cand idate  ge ne for s chizophrenia due t o it s
c h r o m o s o m a l  l o c a t i o n  a n d  n e u r o b i o l o g i c a l  r o l e s .  I n  a  B r i t i s h  l i n k a g e  s t u d y , N O T C H 4  g e n e
polymorphisms were highly associated with schizophrenia. In a Japanese case-control association
study, however, these polymorphisms did not show significant associations with schizophrenia. We
conducted a case-control study with Japanese subjects to explore an association between the
triplet  repeat  polymorphism  in  the  NOTCH4  gene  and  schizophrenia,  including  subtypes  of
s c h i z o p h r e n i a , l o n g i t u d i n a l  d i s e a s e  c o u r s e  c h a r a c t e r i s t i c s , a n d  a  p o s i t i v e  f a m i l y  h i s t o r y  f o r
psychoses.
Methods:  We examined the (CTG)n repeat polymorphism in the NOTCH4 gene among 100
healthy Japanese individuals and 102 patients with schizophrenia (22 paranoid, 38 disorganized, 29
residual, 64 episodic, 31 continuous, 42 with prominent negative symptoms, and 46 with positive
family  histories)  using  a  polymerase  chain  reaction-based,  single-strand  conformational
polymorphism analysis.
Results:  Five different alleles consisting of 6, 9, 10, 11, and 13 repeats of CTG (Leu) in patients
with schizophrenia, and 4 alleles consisting of 6, 9, 10, and 11 repeats in controls were found. No
significant differences in genotype or allele frequencies of repeat numbers were found between
controls and patients. In addition, there were no associations between the polymorphism and
schizophrenia subtypes, longitudinal disease course characteristics, or positive family history of the
patients.
Conclusions:  Our data suggest a lack of association between the NOTCH4 gene triplet repeat
polymorphism and schizophrenia in Japanese individuals.
Background
NOTCH activity affects the implementation of differenti-
ation, proliferation, and apoptotic programs, influencing
organ formation and morphogenesis [1]. The formation
of neuronal contacts results in activation of NOTCH re-
ceptors, leading to the restriction of neuronal growth and
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a subsequent arrest in differentiation [2]. NOTCH func-
tions as a genetic switch between neuronal and glial fates
through its negative regulation of the glial cell deficient/
glial cells missing (glide/gcm) gene, the gene required to
induce gliogenesis in glial precursors [3].
The human NOTCH4 gene is located on chromosome
6p21.3 [4], and several linkage studies have suggested
that a susceptibility locus for schizophrenia is present on
chromosome 6p [5, 6, 7, 8]. In situ hybridization studies
have determined that in embryonic and adult life,
NOTCH4 transcripts are primarily restricted to endothe-
lial cells [9]. NOTCH4 is not necessary for embryonic de-
velopment, as NOTCH4-deficient mice develop
normally. However, this gene and the NOTCH1 gene
have partially overlapping roles during embryogenesis in
mice; both NOTCH1-mutant and NOTCH1/NOTCH4-
double mutant embryos have severe defects in angiogen-
ic vascular remodeling [10].
Using linkage disequilibrium mapping of the human ma-
jor histocompatibility complex (MHC) region in 80 Brit-
ish parent-offspring trios, Wei and Hemmings [11] found
that NOTCH4 was highly associated with schizophrenia.
The A-to-G substitution in the promoter region (SNP2)
and the (CTG)n repeat in exon 1 of NOTCH4 were con-
sidered possible candidate sites conferring susceptibili-
ty. A Japanese case-control association study [12]
reported that these polymorphisms did not show signifi-
cant associations with schizoaffective disorder or schizo-
phrenia in Japanese individuals; further, no associations
were found between the polymorphisms and subcatego-
ries of schizophrenia or a positive family histry of psy-
choses.
We conducted a case-control study using Japanese sub-
jects to explore an association between the (CTG)n re-
peat polymorphism in the NOTCH4 gene and
schizophrenia, and to examine subtypes, longitudinal
disease course characteristics, and a positive family his-
tory of psychoses. We found no association between the
NOTCH4 gene triplet repeat polymorphism and schizo-
phrenia in this patient population.
Methods
DNA Samples
Informed written consent was obtained from subjects
prior to the study according to research protocols ap-
proved by the Ethics Committee of Tsukuba University.
Schizophrenic patients (N = 102) were examined; this
group consisted of 61 men (mean age, 46.2 ±  12.0 years;
mean age at onset of schizophrenia, 25.2 ±  7.4 years) and
41 women (mean age, 47.5 ±  15.5 years; mean age at on-
set of schizophrenia, 27.0 ±  10.6 years) who matched the
DSM-IV criteria for schizophrenia [13]. Patients were
further divided into subtypes (22 paranoid, 38 disorgan-
ized, 4 catatonic, 29 residual, and 9 undifferentiated),
and classified as to longitudinal course specifiers (64 ep-
isodic, 31 continuous, 5 single episode, and 2 other or un-
specified). Furthermore, 42 patients were categorized
with prominent negative symptoms, and 46 patients had
a family history of psychoses in first- or second-degree
relatives.
The control group consisted of 100 unrelated healthy
volunteers (30 men, mean age 32.1 ±  11.4 years and 70
women, mean age 43.1 ±  12.0 years) who were hospital
employees living in the same city as the patients. Each
volunteer was interviewed by 2 psychiatrists in order to
rule out subjects with a family history of mental illness.
All patients and controls were of Japanese origin.
Genomic DNA samples were prepared from whole blood
collected in disodium ethylenediamine tetra-acetic acid
(EDTA; 3 mg/L) according to the sodium iodide method
(DNA Extractor WB Kit, Wako Pure Chemical Indus-
tries, Osaka, Japan).
Polymerase Chain Reaction Conditions
A set of polymerase chain reaction (PCR) primers that
spanned the (CTG)n repeat region in exon 1 was used to
produce DNA fragments. The primers used were NOT-
LR-F (forward): 5'-CCCTGCCTGAAGAGGGACAG-3'
and NOT-LR-R (reverse): 5'-TCTGGGTCTGACCACT-
GAGAC-3'. These primers were designed using informa-
tion from a previous report [4] and the GenBank
sequence (accession number: U89335). The 5'-terminus
of NOT-LR-F was labeled with indodicarbocyanine fluo-
rescent dye (Amersham Pharmacia Biotech, Uppsala,
Sweden) for fluorescence-based, single-strand confor-
mational polymorphism (SSCP) analysis.
The PCR mixture contained the following: 0.5 ng genom-
ic DNA, 0.25 µ M of each primer, 0.2 mM of each deoxy-
nucleotide triphosphate, 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 1.5 mM MgCl2, and 0.5 U of Taq DNA polymer-
ase (HotStarTaq, QIAGEN, Hilden, Germany) in a final
volume of 25 µ l.
The amplification reaction was performed as follows: an
initial denaturation at 95° C for 15 minutes, followed by
35 cycles of denaturation at 94° C for 30 seconds, anneal-
ing at 62° C for 30 seconds, and extension at 72° C for 30
seconds, with a final extension step of 72° C for 10 min-
utes (GeneAmp 9600, PE Applied Biosystems, Foster
City, CA).
PCR products were visualized by ethidium bromide
staining under UV light after electrophoresis on 2% aga-
rose gels.BMC Psychiatry (2001) 1:1 http://www.biomedcentral.com/1471-244X/1/1
SSCP Analysis
A DNA sequencer (ALF express, Amersham Pharmacia
Biotech) was used to perform fluorescence-based SSCP
analysis. PCR products were mixed with loading buffer
containing 99.5% deionized formamide and 0.5% blue
dextran. The solution was denatured at 97° C for 5 min-
utes, then immediately cooled on ice. Single-stranded
PCR products were analyzed by electrophoresis on 7%
polyacrylamide gels (49:1, acrylamide:bisacrylamide ra-
tio) containing 7 M urea in 0.5X Tris-borate-EDTA buff-
er at 50° C. The data were analyzed using the software
package Fragment Manager (Amersham Pharmacia Bio-
tech).
PCR Product Sequencing
PCR products showing altered band patterns by SSCP
analysis were purified by centrifugation to recover the
DNA (Microcon tube, Millipore, Bedford, MA). DNA se-
quences of the PCR products were directly determined
using a Genetic Analyzer (ABI PRISM TM 310, PE Ap-
plied Biosystems) after termination-dideoxy-cycle se-
quencing (Sequencing Reaction Kit-FS, PE Applied
Biosystems) with the forward primer (NOT-LR-F).
Statistical Analysis
Deviation of genotype distribution as derived from the
Hardy-Weinberg equilibrium equation was calculated
using the chi-square test for goodness of fit. Association
analyses were performed using Fisher's exact probability
test (2-sided) using InStat-2.01 (GraphPad Software,
San Diego, CA). Simulations using the Monte Carlo
method [14] were performed using ARLEQUIN (version
2.00, University of Geneva) software.
Results and Discussion
A triplet repeat (CTG)n polymorphism in the NOTCH4
gene was identified by SSCP analysis and confirmed by
direct sequencing of PCR products. As shown in Table 1,
Table 1: Allele frequencies of the CTG repeat in controls and schizophrenic patients, including subtypes, course specifiers and  positive 
family history, and results of Fisher's exact test and Monte Carlo method
Fisher's test Monte Carlo
Subjects (n) Alleles (%) 6R vs 9-13R method
6R 9R 10R 11R 13R P value P value
Controls (100) 38 (19.0) 72 (36.0) 78 (39.0) 12 (6.0) 0 (0.0) 0.7095 0.9547
Schizophrenic patients (102) 42 (20.6) 67 (32.8) 80 (39.2) 14 (6.9) 1 (0.5) 0.7095 0.9547
Subtypes
Paranoid (22) 10 (22.7) 13 (29.5) 17 (38.6) 4 (9.1) 0 (0.0) 0.5378 0.7538
Disorganized (38) 21 (27.6) 27 (35.5) 23 (30.3) 4 (5.3) 1 (1.3) 0.1392 0.3808
Residual (29) 8 (13.8) 18 (31.0) 28 (48.3) 4 (6.9) 0 (0.0) 0.4386 0.6666
Others (13) 3 (11.5) 9 (34.6) 12 (46.1) 2 (7.7) 0 (0.0) 0.4304 0.7869
Course
Episodic (64) 24 (1 8.8) 48 (37.5) 45 (35.2) 10 (7.8) 1 (0.8) 1.0000 0.9207
Continuous (31) 15 (24.2) 15 (24.2) 28 (45.2) 4 (6.5) 0 (0.0) 0.3709 0.4709
Others (7) 3 (21.4) 4 (28.6) 7 (50.0) 0 (0.0) 0 (0.0) 0.7346 0.8137
Prominent negative symptoms (42) 17 (20.2) 26 (31.0) 34 (40.5) 6 (7.1) 1 (1.2) 0.8696 0.8388
Positive family history (46) 19 (20.7) 31 (33.7) 34 (37.0) 7 (7.6) 1 (1.1) 0.7522 0.9002
6R, 9R, 10R, 11R and 13R indicate 6, 9, 10, 11 and 13 repeats of CTG, respectively.BMC Psychiatry (2001) 1:1 http://www.biomedcentral.com/1471-244X/1/1
5 different alleles consisting of 6, 9, 10, 11, and 13 repeats
(6R, 9R, 10R, 11R, and 13R) of CTG (Leu) in patients with
schizophrenia, and 4 alleles consisting of 6R, 9R, 10R,
and 11R in controls were found. No significant differenc-
es in genotype or allele frequencies of repeat numbers
were found between controls and patients. In addition,
there were no associations between the polymorphism
and subtypes, longitudinal disease course characteris-
tics, or family history of psychoses.
The British linkage study [11] revealed that an excess of
the (CTG)10 allele was transmitted to affected offspring
by their parents. In our comparison of the frequency of
the 10R allele with the other alleles (6R+9R+11R+13R),
no significant differences were found between controls
and patients with schizophrenia.
Previous study [12] and our study using random samples
found no association between the polymorphism and
schizophrenia. Possible reasons for disagreement with
the British study [11] depend on the differences of ethnic-
ity, population admixture, sample size and methodology.
Wei and Hemmings [11] used the Transmission Disequi-
librium Test, while our study employed a case-control
design, which might produce false positive or negative
findings due to stratification problems [15]. Further
study using a larger sample size and the investigation of
more SNPs in coding regions will be necessary to confirm
the relationship between the NOTCH4 gene and schizo-
phrenia.
Conclusions
Our study suggests a lack of association between the tri-
plet repeat (CTG)n polymorphism in the NOTCH4 gene
and schizophrenia in Japanese patients.
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